

Guido Lancman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7073608/publications.pdf>

Version: 2024-02-01

25
papers

386
citations

1040056

9
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

680
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 131.	17.0	78
2	Impact of rituximab on COVID-19 outcomes. <i>Annals of Hematology</i> , 2021, 100, 2805-2812.	1.8	46
3	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2616.	4.8	44
4	Bispecific Antibodies in Multiple Myeloma: Present and Future. <i>Blood Cancer Discovery</i> , 2021, 2, 423-433.	5.0	43
5	Nonconvulsive status epilepticus in patients with brain tumors. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014, 23, 542-547.	2.0	40
6	Bispecifics, trispecifics, and other novel immune treatments in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 264-271.	2.5	40
7	Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 900-904.	2.4	19
8	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e470-e476.	0.4	12
9	Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. <i>Targeted Oncology</i> , 2020, 15, 697-708.	3.6	11
10	Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19. <i>Annals of Hematology</i> , 2021, 100, 833-835.	1.8	11
11	The effect of novel therapies in high-molecular-risk multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 870-879.	0.3	10
12	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. <i>Blood</i> , 2020, 136, 6-7.	1.4	8
13	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021, 138, 2704-2704.	1.4	6
14	Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?. <i>Expert Review of Hematology</i> , 2017, 10, 23-28.	2.2	5
15	Practicing Antimicrobial Stewardship: De-Escalating Antibiotics in Patients With Acute Myeloid Leukemia and Neutropenic Fever. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa138.	0.9	4
16	Ruxolitinib for steroid-refractory graft-versus-host disease: A case series. <i>Hematological Oncology</i> , 2018, 36, 611-613.	1.7	3
17	Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 171-174.	0.9	3
18	Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients. <i>Leukemia Research</i> , 2019, 77, 1-4.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients. <i>Blood</i> , 2019, 134, 3849-3849.	1.4	1
20	Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2018, 12, 1-3.	0.3	1
21	1090. Practicing Antimicrobial Stewardship: De-escalating Empiric Antibiotics in Patients with Acute Myelogenous Leukemia and Neutropenic Fever. <i>Open Forum Infectious Diseases</i> , 2019, 6, S387-S388.	0.9	0
22	Plasma hemoglobin in COVID-19: authorsâ€™ reply. <i>Annals of Hematology</i> , 2021, 100, 2127-2127.	1.8	0
23	The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 5784-5784.	1.4	0
24	Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy. <i>Blood</i> , 2019, 134, 5102-5102.	1.4	0
25	An Opportunity for Hospice Referral in Acute Myeloid Leukemia: Prognostic Significance of Hospitalization Status at Time of Second Cycle of Hypomethylating Agents for Patients Ineligible for Intensive Induction Chemotherapy. <i>Journal of Palliative Medicine</i> , 2020, 23, 1424-1425.	1.1	0